Pricing Log in Create free account
Friday 6 November 2026 Export BNR’s income statement to Excel — free account

Burning Rock Biotech Limited Sponsored ADR

BNR Healthcare Diagnostics & Research

Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024.

Revenue
−4.22%
EPS
−98.4%
Free cash flow
+46.0%
Total debt
−5.02%

Quarter to June 2026, against a year earlier

13.20 0.37 +2.88%
Market cap
$116.5M
P/E
0.0×
Fwd P/E
11.1×
Dividend yield
—
F-score
5/9
Altman Z
−2.95
Beneish M
−2.47
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 11.65
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 1 — — 1 — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 91.93%

Capital & Financial Ratios $m

Size
Market Cap 116.47
Revenue ttm 73.59
Net income ttm (7.92)
Free cash flow ttm (2.21)
Net debt Q (61.50)
Valuation
P/E 0.00
Forward P/E 11.10
Price / sales 19.48 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 19.57 (above 6: high)
Financial health
Current ratio Q 3.05 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (1,326.50)
Growth
Revenue growth Q −4.22% (below 0%: shrinking)
Operating income growth Q −65.30% (below 0%: shrinking)
EPS, this year —
EPS, next year A —
Revenue, next year A +3,217.16% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +5.10%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 18.6×, against a ten-year median of 4.4×; over the ten years it ranged from −0.1× in 2024 to 589× in 2021.
P/S against its own 10 years 77.10%
10-year low 10-year high
P/B against its own 10 years 92.30%
10-year low 10-year high
EV/Sales against its own 10 years 77.36%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 87 72 69 62
Receivables 18 21 24 25
Inventory 10 9 7 5
Other 3 2 3 2
125 106 106 98
2023 2024 2025 Q'26
Payables 3 5 6 3
ST’ Debt — — 0 0
Other 0 0 0 0
37 36 35 32

Compound Annual Growth %

10y 5y 3y
Sales — 3.21% (1.87%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (27.07%) (23.04%)

Earnings Trends EPS, adjusted, against the consensus

Mar 2023 Estimate −2.00 Actual −2.60

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Mar 2022 −2.30 −3.90 Miss by 1.60
Jun 2022 −3.60 −3.70 Miss by 0.10
Sep 2022 −2.80 −3.10 Miss by 0.30
Mar 2023 −2.00 −2.60 Miss by 0.60

EPS $

Mar Jun Sep Dec Year
’26 (0.02) (0.02) — — —
’25 (0.02) (0.01) (0.26) (0.21) (0.73)
’24 (0.16) (0.14) (0.05) (1.08) (4.61)
’23 (2.60) (1.80) (2.30) (2.20) (9.00)
’22 (3.90) (3.70) (3.10) (3.10) (13.60)
’21 (2.50) (3.00) (2.50) (3.80) (12.00)
’20 (0.11) (2.47) (1.80) (0.23) (10.50)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 16 20 — — —
’25 18 21 18 20 77
’24 17 19 18 16 71
’23 21 20 17 17 76
’22 21 20 22 19 82
’21 16 20 20 24 80
’20 10 15 18 20 66
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (3) (6) 2 3 (4)
’24 (6) (6) (5) 3 (13)
’23 (16) (10) (6) (3) (36)
’22 (23) (15) (17) (12) (66)
’21 (17) (19) (21) (18) (75)
’20 (1) 9 3 (13) (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (3) (6) 2 3 (5)
’24 (6) (6) (5) 3 (13)
’23 (16) (10) (6) (3) (37)
’22 (23) (15) (17) (12) (76)
’21 (17) (19) (21) (18) (108)
’20 (1) 9 3 (13) (23)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 16 32 55 66 80 82 76 71 77 74 +21.3% 2,559 — — +3,217.2%
Gross margin, % — 64.49 64.66 71.61 73.02 71.70 67.47 67.58 70.25 74.67 74.50 +10.2 pt
EBT — (19) (27) (24) (62) (125) (141) (92) (47) (8) (10) (10.9%)
EBT margin, % — (118.09) (84.98) (44.32) (94.73) (156.70) (172.08) (121.19) (66.06) (9.97) (13.19) +108.1 pt
Net income — 0 (27) 0 (62) (125) (141) (92) (47) (8) (8) n/m
Per share, $
Per share, $ Revenue — 0.16 0.30 0.53 9.60 7.65 7.86 7.39 6.87 7.26 0.68 +61.3%
Earnings — (0.26) (0.34) (0.47) (10.50) (12.00) (13.60) (9.00) (4.61) (0.73) (0.52) +13.8%
Cash flow — (0.19) (0.22) (0.32) (1.64) (7.20) (6.37) (3.52) (1.23) (0.38) (0.02) +9.1%
Capex — 0.00 0.00 0.00 (1.76) (3.21) (0.95) (0.13) (0.06) (0.06) 0.00 n/m
Free cash flow — (0.19) (0.22) (0.32) (3.40) (10.40) (7.32) (3.65) (1.29) (0.44) (0.02) +11.1%
Book value — 0.00 (0.01) 0.88 54.06 27.79 16.16 10.57 7.73 7.20 0.67 n/m
Shares, m — 104 104 104 7 10 10 10 10 11 59 (24.8%)
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — 0.00 0.00 0.00 381.27 12.46 2.75 1.31 0.98 2.78 19.48 44.6
P/B — 0.00 0.00 0.00 64.79 3.43 1.34 0.92 0.87 2.80 19.57 8.2
EV/Sales — 0.00 0.00 0.00 375.83 9.60 1.20 0.20 0.01 1.89 18.64 43.2
EV/FCF — 0.00 0.00 0.00 (8,207.08) (10.21) (1.47) (0.17) (0.02) (8.83) (93.69) (914.2)
Cash, $m
Cash, $m Operating cash flow — (20) (22) (33) (11) (75) (66) (36) (13) (4) (2) (17.9%)
Capex — (3) (4) (7) (12) (33) (10) (1) (1) (1) (12) (19.0%)
Free cash flow — (20) (22) (33) (23) (108) (76) (37) (13) (5) (2) (16.5%)
Balance, $m
Balance, $m Working capital — — 1 76 350 227 123 87 70 70 66 +78.7%
Net debt — — 20 (49) (344) (228) (127) (87) (72) (69) (62) n/m
Shareholders’ equity — — (1) 91 371 290 168 108 80 77 73 n/m
Returns, %
Returns, % ROA — 0.00 (129.38) (178.19) (31.28) (32.66) (47.92) (48.89) (35.47) (6.64) (8.81) (6.6) pt
ROIC — — 0.00 0.00 (146.67) (126.40) (216.16) (273.06) (380.90) (61.14) (50.66) (61.1) pt
ROE — 0.00 32.53 44.80 (59.51) (37.85) (61.56) (66.68) (50.57) (10.14) (13.08) (10.1) pt
People
People Employees — — — 753 938 1,394 1,138 786 674 667 — (2.0%)
Revenue/emp, $m — 0.00 0.00 0.07 0.07 0.06 0.07 0.10 0.10 0.12 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Burning Rock Biotech Limited Sponsored ADR vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MYGN Myriad Genetics, Inc. $601.6M — (loss-making) — (loss-making) −10.51% (below 0%: shrinking) n/m +43.90% (above 0%: growing) 66.60% (20.40%) Compare
FLGT Fulgent Genetics, Inc. $513.4M — (loss-making) — (loss-making) +7.54% (above 0%: growing) n/m +2,058.74% (above 0%: growing) 35.33% (24.94%) Compare
BDSX Biodesix, Inc. $209.3M — (loss-making) — (loss-making) +10.44% (above 0%: growing) n/m +12.78% (above 0%: growing) 0.00% (25.42%) Compare
XGN Exagen Inc. $184.1M — (loss-making) — (loss-making) +15.92% (above 0%: growing) n/m +211.34% (above 0%: growing) 61.27% (8.64%) Compare
BNR Burning Rock Biotech Limited Sponsored ADR $116.5M — (loss-making) 11.1× −4.22% (below 0%: shrinking) n/m +46.01% (above 0%: growing) 72.58% (13.36%)
MDXHF MedX Health Corp. $103.2M — (loss-making) — (loss-making) +33.59% (above 0%: growing) n/m +41.60% (above 0%: growing) 37.19% (1,027.95%) Compare
IMDX Insight Molecular Diagnostics Inc. $80.5M — (loss-making) — (loss-making) −53.86% (below 0%: shrinking) n/m −54.02% (below 0%: shrinking) 65.69% (4,770.71%) Compare
QUCY Quantum Cyber N.V $60.8M — (loss-making) — (loss-making) +11.12% (above 0%: growing) n/m +26.73% (above 0%: growing) 62.71% 0.00% Compare
PRPO Precipio, Inc. $33.3M — (loss-making) 15.4× +24.18% (above 0%: growing) n/m +79.59% (above 0%: growing) 44.67% (8.53%) Compare
Median of peers $143.6M — — +10.78% — +42.75% 52.97% (22.67%)

All 49 Diagnostics & Research stocks →

Burning Rock Biotech Limited Sponsored ADR (BNR) Latest News

10 Sep

Impact 4 · earnings

9 Jun

Impact 3 · · GlobeNewswire

2 Apr

Impact 4 · · GlobeNewswire

12 Mar

Impact 4 ·

5 Jan

Impact 3 · · GlobeNewswire

22 Dec

Impact 3 · · GlobeNewswire

26 Nov

Impact 4 · · Barchart

20 Nov

Impact 3 · · GlobeNewswire

24 Sep

Impact 4 · · GlobeNewswire

8 Sep

Impact 3 · · GlobeNewswire

16 Jul

Impact 3 · · Simply Wall St.

6 Jun

Impact 3 ·

25 Mar

Impact 4 · · GlobeNewswire

31 Dec

Impact 3 ·

5 Dec

Impact 4 ·

3 Dec

Impact 3 ·
Impact 3 · · GlobeNewswire

8 Nov

Impact 4 · · Simply Wall St.

10 Oct

Impact 4 · · GlobeNewswire

27 Sep

Impact 3 · · GlobeNewswire

22 Aug

Impact 4 · · GlobeNewswire

19 Aug

Impact 3 · · GlobeNewswire

11 Jul

Impact 3 · · Simply Wall St.

30 May

Impact 4 · · GlobeNewswire

29 May

Impact 4 · · Thomson Reuters StreetEvents
Impact 3 · · GlobeNewswire

23 May

Impact 3 · · GlobeNewswire

14 May

Impact 3 · · GlobeNewswire

29 Apr

Impact 3 · · GlobeNewswire

26 Apr

Impact 3 · · GlobeNewswire
stockrow.com/BNR · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com